IonQ ends the week in a materially different position than the one described in last week's note: the borrow squeeze that defined mid-September has largely unwound, the stock has added another 7.8% to close at $43.91, and Bank of America has just initiated coverage with a Buy.
The reversal in the lending market is the clearest change from last week's note. Availability has more than doubled in five sessions, rising from 8.2% to 21.3%. That means the pool is still tight, roughly one share available for every four already lent out, but the acute squeeze conditions that prevailed through the 21st to 25th have eased. The 52-week low remains 0.1%, so the current level is not loose by any measure, but the direction has shifted. Cost to borrow has also retreated, falling 17% on the week to 0.85%, its lowest reading in the 30-day window. Short interest itself has dipped marginally, down 1.4% on the week to 11.4% of the free float. That is still a meaningful short position, and the fact that it has barely moved through a stock that is up roughly 18% over the past month points to a cohort of shorts that remain unconvinced rather than trapped. Options positioning is broadly neutral: the put/call ratio of 0.82 sits almost exactly in line with its 20-day average and near the lower half of its 52-week range, suggesting no particular anxiety in the derivatives market.
The Street angle is the most newsworthy development this week. Vivek Arya at B of A Securities initiated coverage on September 28 with a Buy and a $60 target. That sits below the consensus mean of $66.63 across 11 buy-rated analysts, with Wedbush holding at $75 and Rosenblatt at $100 at the bullish end. Mizuho is the outlier, having cut its target from $61 to $52 on September 9 while keeping an Outperform, a signal that at least one firm sees the current price as having run ahead of near-term fundamentals. The analyst recommendation divergence factor scores in the 97th percentile across the ORTEX universe, reflecting unusually strong directional agreement even with that one trim. The EPS surprise factor ranks in the 96th percentile. Against those positives, the ORTEX short score of 64.5 places the stock in the 6th percentile for short positioning, meaning it carries more short pressure than 94% of names in the universe. The bear case is not subtle: IonQ remains pre-profitability, EV/EBITDA is deeply negative, and with the bear case citing an EV/Sales ratio of roughly 24x on estimated 2035 revenue, the valuation asks a lot of things to go right over a long horizon.
Retail attention, tracked via Wikipedia pageviews, is running at a z-score of 3.65 versus the stock's own 90-day history, the highest reading in the dataset window. That is an attention measure, not a revenue signal, but it does suggest the stock is attracting a wider audience than usual, likely driven by the BofA initiation and the continued price rally.
The institutional register shows no activist presence. Morgan Stanley crossed above 5% on a 13G filed in August, rising from 4.8% to 5.6%, while BlackRock's disclosed stake has fallen from 7.8% to 5.3% over the same period. Both are passive holders. Insider activity over the past 90 days nets to a small negative: the CEO and CFO each had shares withheld for tax on September 11 (transaction code F, a compensation mechanic rather than a discretionary sale), and one director sold a modest position under a pre-arranged 10b5-1 plan. None of that reads as conviction selling.
The next earnings print is scheduled for November 4, five weeks out. The most recent quarterly result on August 5 saw the stock fall 4.8% on the day before recovering to post an 8.3% gain over the following five sessions. With short interest still elevated, availability still relatively tight, and a fresh Buy initiation now on the record, how that recovery pattern repeats, or breaks, around the November release will be the defining test for this setup.
See the live data behind this article on ORTEX.
Open IONQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
